Colonoscopic Removal of Adenomas Cuts CRC Mortality

Share this article:
Colonoscopic Removal of Adenomas Cuts CRC Mortality
Colonoscopic Removal of Adenomas Cuts CRC Mortality

(HealthDay News) -- Colonoscopic removal of adenomatous polyps reduces colorectal cancer mortality, and interim analysis shows that fecal immunochemical testing (FIT) yields similar results to colonoscopy; however, more polyps are identified with colonoscopy screening compared to FIT, according to two studies published in the Feb. 23 issue of the New England Journal of Medicine.

Ann G. Zauber, Ph.D., from the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues investigated the long-term effect of colonoscopic polypectomy in 2,602 patients who had adenomas removed between 1980 and 1990. Patients were followed for a median of 15.8 years, during which time, 1,246 patients died from any causes and 12 died from colorectal cancer. The standardized incidence-based mortality ratio was 0.47 with colonoscopic polypectomy, based on an estimated 25.4 expected deaths from colorectal cancer in the general population.

Enrique Quintero, M.D., Ph.D., from the Hospital Universitario de Canarias in Tenerife, Spain, and colleagues conducted a randomized trial in asymptomatic adults aged 50 to 69 years, comparing one-time colonoscopy in 26,703 adults with FIT every two years in 26,599 adults. The researchers found that, compared with the colonoscopy group, the rate of participation in the FIT group was significantly higher (34.2 versus 24.6 percent; P < 0.001). Colorectal cancer was found in 0.1 percent of both groups. Advanced adenomas were detected in 1.9 and 0.9 percent of the colonoscopy and FIT groups, respectively (odds ratio, 2.30; 95 percent confidence interval [CI], 1.97 to 2.69; P < 0.001), and nonadvanced adenomas were detected in 4.2 and 0.4 percent, respectively (odds ratio, 9.80; 95 percent CI, 8.10 to 11.85; P < 0.001).

"The numbers of subjects in whom colorectal cancer was detected were similar in the two study groups, but more adenomas were identified in the colonoscopy group," Quintero and colleagues write.

Eiken Chemical of Japan, Palex Medical, and Biogen Diagnóstica donated supplies and automated analyzers used for FIT in the Quintero study.

Full Text - Zauber (subscription or payment may be required)
Full Text - Quintero (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Statins may lower progression risk for renal cancer

Statins may lower progression risk for renal cancer

Use of statins is associated with a reduced risk of progression of localized renal cell carcinoma, according to research.

Cyramza approved by FDA for stomach cancer

Cyramza approved by FDA for stomach cancer

Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach.

Cancer patients require anxiety and depression screening

Cancer patients require anxiety and depression screening

It is important to recognize and treat anxiety or depression among cancer patients, according to a clinical guideline published in the Journal of Clinical Oncology.